# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12018074
Maxim Group analyst Michael Okunewitch initiates coverage on Chemomab Therapeutics (NASDAQ:CMMB) with a Buy rating and annou...
Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.28) per share. This is a 65 percent increase over losses o...
Oppenheimer analyst Jeff Jones upgrades Chemomab Therapeutics (NASDAQ:CMMB) from Perform to Outperform and announces $6 pric...
Longitudinal Study of a 200+ Real-World Patient Cohort Further Validates CCL24 as a Novel Target for Systemic Sclerosis (SSc), ...